Compare M&T Bank Corporation (MTB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs TG Therapeutics Inc — how do they compare? M&T Bank Corporation trades at $251.93 (market cap $36.42B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: M&T Bank Corporation is far larger — about 4.8× TG Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTB | TGTX | |
|---|---|---|
Market Cap | $36.42B | $7.64B |
Sector | Financials | Health |
52-Week High | $254.04 | $59.06 |
52-Week Low | $178.63 | $26.94 |
Dividend Yield | 2.38% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $253.46, up 0.93% today, near its consensus price target of $255.92. The stock shows bullish technical momentum, with recent earnings consistently beating estimates, including Q2 2026 EPS of $5.35 versus $4.66 expected. Revenue growth is steady, with 2025 revenue at $9.63 billion and net income margin improving to 29.59%. The company maintains a solid dividend, paying $1.50 in H1 2026.
Outlook remains positive supported by strong fundamentals and analyst consensus, though risks include macroeconomic sensitivity and elevated investing cash outflows. The stock presents a value opportunity with a P/E of 13.35 and bullish institutional sentiment, but investors should monitor interest rate impacts and loan growth sustainability.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
